We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
Figure 2

Figure 2. From: Phase II trial of hul4.18-IL2 for patients with metastatic melanoma.

Mean peripheral blood lymphocyte count (cell number per mcl +/− SD) at the indicated protocol day for the 14 patients in this study. Timepoints are pretreatment (Pre) and at the indicated cycle (C) and day (D) of that cycle. Changes from Pre were significant for C1D3, C1D8, C2D3, C2D26 (p < 0.001) and C1D26 (p = 0.011)

Mark R Albertini, et al. Cancer Immunol Immunother. ;61(12):2261-2271.
2.
Figure 1

Figure 1. From: Phase II trial of hul4.18-IL2 for patients with metastatic melanoma.

Antibody-dependent cell-mediated cytotoxicity (ADCC) with hu14.18-IL2 in patient serum. The M21 human melanoma target (% cytotoxicity; effector:target ratio of 50:1) was evaluated with (+) and without (−) effector PBMC from a healthy control donor in medium containing patient serum obtained pretreatment (pre) or after the initial 4 hour hu14.18-IL2 infusion (4 hr).

Mark R Albertini, et al. Cancer Immunol Immunother. ;61(12):2261-2271.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk